JNJ - J&J says Rybrevant combo bests AstraZeneca's Tagrisso in type of lung cancer
2024-05-31 17:53:13 ET
More on Johnson & Johnson
- Johnson & Johnson: Market Will Regret The Overreaction
- Johnson & Johnson: Vital Signs Decent, A Compelling Value Case
- J&J completes acquisition of cardiac device maker Shockwave
- Johnson & Johnson depression candidate seltorexant meets phase 3 goals
- Johnson & Johnson (JNJ) Bernstein's 40th Annual Strategic Decisions Conference - (Transcript)